Five weeks ago, brands across the EU pulled stock off shelf that contained silver, perboric acid, acetone oxime and twelve other CMR-classified ingredients. Commission Regulation (EU) 2026/78 came into force on 1 May with no grace period. The brands that had been treating EU annex monitoring as an occasional task got caught. The brands that had been treating it as an operating function quietly reformulated, re-notified and shipped.
The same regulatory machinery that produced May's ban is now in the early stages of the next wave. The Commission has opened the consultation window for heliotropin, an aromatic aldehyde widely used in fine fragrance and personal care. Stakeholder comments close on 15 June 2026.
If you are a beauty operator and that sentence read like background noise, the cost of that reading is high. Heliotropin is in more SKUs than most founders realise. The window to influence the proposal closes in two weeks. Once it closes, the regulation hardens, the classification moves to formal vote, and the path from "proposal" to "shelf clearance deadline" follows the same six to nine month track that delivered May's deadline. There is no separate grace period. There is no informal extension. The brands that engage in the window get heard. The brands that do not, do not.
What heliotropin is and where it lives
Heliotropin is a vanilla-cherry-almond aromatic aldehyde. It is the warm, slightly nutty note that anchors a long list of mass and prestige fragrances, particularly in the gourmand and orientale families. It is also used in scented personal care, including body care, hair care, and some skincare in the wellness and aromatherapy segments. It is on the IFRA list. It is one of the most-used heliotrope-family materials in formulation.
The CMR proposal under review classifies heliotropin under category 2 reproductive toxicity. That is the same regulatory bucket that delivered the May ban list. The Commission has signalled, in its early communications, that ingredients reaching this classification through SCCS opinion typically move to restriction or prohibition unless the comment window produces substantive industry evidence that changes the risk assessment.
The exposure for a £500k-£5m brand depends on category. Fine fragrance brands are the most directly exposed. Personal care brands with scented bases, particularly body care, hair care and bath products in the aromatherapy and wellness segments, are next. Skincare brands using fragranced formulations in the mid to premium tier sit just behind that. Unscented or fragrance-free SKUs are unaffected.
The complication is that brands often do not know whether their fragrance bases contain heliotropin. The information sits with the fragrance house, behind a confidential composition. The brand sees an IFRA certificate and a CAS list, not the full formula. The first step in the exposure audit is asking the fragrance supplier, in writing, whether heliotropin is in any of the bases you use, in any of the SKUs you sell into the EU.
How the comment window actually works
The EU CMR review process is more open than it looks from the outside. The Commission accepts comments from any stakeholder during the published window. The comments that get weighted heavily are the ones with substantive evidence: new toxicology data, real-world exposure modelling, alternative classification arguments grounded in newer SCCS opinions, or specific use-case data that the original proposal did not consider.
The comments that get filed and ignored are the ones that read as opinions. "This ingredient is widely used" is not an argument. "Banning this ingredient will harm small businesses" is not an argument. The Commission has heard both, for every CMR review, since the framework was set up.
For an indie brand, the realistic path into the comment window is through one of three channels. The first is direct submission, written formally, citing the proposal by name and submitting evidence the brand has commissioned or has access to. The second is through the relevant trade body, including Cosmetics Europe at EU level and country-level bodies. The third is through the fragrance supplier, which usually files its own comments and will sometimes incorporate downstream-customer evidence into its submission if asked early enough.
For a £500k-£5m brand, the realistic move is option two or three. Cosmetics Europe and the British Beauty Council both file structured submissions and accept member input. Fragrance suppliers including IFF, Givaudan, Symrise and Firmenich track CMR reviews tightly and welcome customer signals about commercial impact.
What happens if heliotropin follows the May 2026 pattern
If the comment window closes without a successful intervention, the proposal moves to formal SCCS opinion, then to Commission vote, then to publication. The current track record suggests this sequence completes within six to nine months of the comment window closing.
Once the regulation publishes, the timeline to shelf clearance depends on the specific text of the regulation. Most recent CMR bans have included a short transition period for placement on the market (the date after which products containing the ingredient cannot be sold by the manufacturer) and a separate longer period for making available on the market (the date after which products cannot be sold by retailers). The May 2026 bans used a single short window for both, which is the harshest version. There is no rule that the next wave has to use the same compression.
For brands that miss the comment window and find themselves planning for a heliotropin ban in early 2027, the operational path is reformulation, re-notification through CPNP, retail communication and stock management. Reformulation typically takes three to six months once the substitution path is identified. CPNP re-notification is administratively quick if the rest of the dossier is current. The pinch point is retail communication and stock management, which is where May 2026's casualties were concentrated.
The 14-day action plan
If you formulate with heliotropin, or if you sell scented EU SKUs and have not confirmed, the next 14 days are the inflection point.
Day one, write to every fragrance supplier on your active SKU list. Ask, in writing, whether heliotropin is present in any base they have supplied for the EU market, in any SKU you currently sell. Set a five-day deadline for response.
Day six, with the supplier responses in, map your exposure. List the affected SKUs, the volume each contributes to revenue, the EU markets each ships to, and the retail commitments each is tied to.
Day eight, decide whether to file a submission. If your exposure is meaningful and you have substantive evidence (real-world exposure data, alternative classification arguments, commercial use-case data), file directly or through a trade body. If your exposure is meaningful but you do not have substantive evidence, brief the trade body and the fragrance supplier on commercial impact so they can incorporate your data into their submission.
Day twelve, begin the parallel reformulation conversation. Do not wait for the regulation to publish to start identifying substitution paths. The fragrance suppliers have alternatives. The reformulation cost is lower if you scope it now than if you scope it in panic six months from now.
Day fifteen, document the audit. Whether or not the regulation comes through, the documentation is the asset. It is what protects you next time a CMR review starts. The brands that survive these waves with the lightest scars are the ones that built annex monitoring into their operating cadence and stopped treating regulation as a one-off project.
The comment window is open. It closes on Sunday week. The cost of engaging is small. The cost of missing is the same one a lot of brands paid in May.